Biotech Values

[mskatiescarletohara]

Re:Oxigene----

They have six ongoing trials to my knowledge, all early stage clinical.

Management did address the cardiac toxicity issues in a conference call a couple of years ago, right after or just before BMY pulled out of the CA4P collaboration. They acknowledged it, however, expressed they did not feel it was a major issue. I think someone from Prudential awhile back within the last year asked about those issues again, and management tip-toed around answering the question directly.

Bottom line is CA4P can induce qLT prolongation; patients taking it must be monitored closely, and those suffering from cardiac problems must be excluded from the enrolling. Folks who are elderly, and not in good cardiovascular health should steer clear.

If BP ever partners, they will have to spend millions on proving safety, especially now with more and more scrutiny from consumers, doctors, health agencies, etc...keeping the FDA on their toes.

Kokostrollet will NEVER say anything bad or negative about OXGN.

katie...